Predictors of persistent ADHD: an 11-year follow-up study
- PMID: 20656298
- PMCID: PMC3068747
- DOI: 10.1016/j.jpsychires.2010.06.009
Predictors of persistent ADHD: an 11-year follow-up study
Abstract
Objective: Despite the existence of several follow-up studies of children with ADHD followed up into adulthood, there is limited information on whether patterns of persistence and remission in ADHD can be predicted over the long term. The main aim of this study was to evaluate predictors of persistence of ADHD in a large sample of boys with and without ADHD followed prospectively for 11 years into young adulthood.
Method: Subjects were Caucasian, non-Hispanic boys with (N = 110) and without (N = 105) ADHD who were 6-17 years old at the baseline assessment (mean age 11 years) and 15 to 31 years old at the follow-up assessment (mean age 22 years). Subjects were comprehensively and blindly assessed with structured diagnostic interviews and assessments of cognitive, social, school, and family functioning.
Results: At the 11-year follow-up, 78% of children with ADHD continued to have a full (35%) or a partial persistence (subsyndromal (22%), impaired functioning (15%), or remitted but treated (6%)). Predictors of persistence were severe impairment of ADHD, psychiatric comorbidity, and exposure to maternal psychopathology at baseline.
Conclusions: These findings prospectively confirm that persistence of ADHD over the long term is predictable from psychosocial adversity and psychiatric comorbidity ascertained 11 years earlier.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Mr. Carter Petty reports no potential conflicts of interest.
Ms. Allison Clarke reports no potential conflicts of interest.
Ms. Alexandra Lomedico reports no potential conflicts of interest.
In the past year, Dr. Stephen Faraone has received consulting fees and has been on Advisory Boards for Eli Lilly, Ortho-McNeil and Shire Development and has received research support from Eli Lilly, Pfizer, Shire and the National Institutes of Health. In previous years, Dr. Faraone has received consulting fees or has been on Advisory Boards or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. In previous years he has received research support from Eli Lilly, Shire, Pfizer and the National Institutes of Health.
Figures
References
-
- Achenbach TM. Manual for the Child Behavior Checklist/4–18 and the 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry; 1991.
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition Text Revision (DSM-IV-TR) 4. Washington, DC: American Psychiatric Association; 2000.
-
- Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry. 1990;29:546–557. - PubMed
-
- Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. Journal of Abnormal Psychology. 2002;111:279–89. - PubMed
-
- Biederman J, Faraone S, Mick E, Lelon E. Psychiatric comorbidity among referred juveniles with major depression: fact or artifact? Journal of the American Academy of Child and Adolescent Psychiatry. 1995a;34:579–590. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
